In response to ongoing concerns over the abuse and misuse of prescription painkillers, the FDA is now requiring class-wide safety labeling changes and new post-market study requirements for all extended-release and long-acting opioid analgesics in hopes of reducing inappropriate prescribing. This group of drugs, which is already subject to a Risk Evaluation Mitigation Strategy, includes OxyContin and Opana ER. The move is the latest bid to thwart what many public health and law enforcement officials describe as an epidemic of deaths and accidental addictions due to the rising use of these medicines.
Help employers find you! Check out all the jobs and post your resume.
